Skip to main content

Table 4 Economic results of PCVs for Peru

From: Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru

 

PCV-7

PCV-13

PHiD-CV

 

Costs averteda

%

Costs averteda

%

Costs averteda

%

All ID

138,603

10.0

190,893

10.2

188,650

8.3

 Meningitis (all)

19,386

1.4

26,641

1.4

26,392

1.2

 Meningitis sequelae (all)

80,789

5.8

110,947

5.9

109,835

4.8

 Bacteremia (all)

38,428

2.8

53,305

2.9

52,423

2.3

Pneumonia

1,008,424

72.7

1,153,782

61.8

1,153,845

50.7

All AOM

240,962

17.4

521,999

28.0

935,558

41.1

Total direct medical costs

1,387,989

100

1,866,674

100

2,278,053

100

Vaccination cost

−23,727,362

 

−25,487,635

 

−22,393,203

 

Net total cost

−22,339,373

 

−23,620,961

 

−20,115,150

 
  1. aUndiscounted costs in 2009 US$.
  2. A negative value indicated costs incurred.
  3. AOM, acute otitis media; ID, invasive disease; PCV-7, 7-valent pneumococcal conjugate vaccine; PCV-13, 13-valent pneumococcal conjugate vaccine; PHiD-CV, 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine.
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us